Characteristic | n (%) or median (range) |
---|---|
Sex | |
Male | 46 (82.14%) |
Female | 10 (17.86%) |
Age (years) | 61 (34–84) |
Karnofsky performance status (10%) | |
≤ 80 | 34 (60.71%) |
> 90 | 22 (39.29%) |
Hepatitis B virus | |
Positive | 49 (87.5%) |
Negative | 7 (12.5%) |
Stagea | |
II | 13 (23.21%) |
III | 25 (44.64%) |
IV | 18 (32.14%) |
Treatment strategy | |
RT alone | 9 (16.07%) |
RT combined with TACE | 47 (83.93%) |
Prescription dose for liver tumor (cGy) | 5400 (4500–6200) |
Live tumor(cm3) | 151.81 (4.20–976.93) |
Plan target volume for liver tumor(cm3) | 342.29 (19.20–1442.27) |